Equities Analysts Issue Forecasts for AGIO FY2026 Earnings

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Investment analysts at HC Wainwright reduced their FY2026 earnings per share estimates for shares of Agios Pharmaceuticals in a report released on Monday, June 9th. HC Wainwright analyst E. Bodnar now expects that the biopharmaceutical company will post earnings per share of ($8.44) for the year, down from their prior estimate of ($8.35). HC Wainwright currently has a “Buy” rating and a $58.00 price objective on the stock. The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($6.85) per share. HC Wainwright also issued estimates for Agios Pharmaceuticals’ FY2027 earnings at ($9.38) EPS, FY2028 earnings at ($8.48) EPS and FY2029 earnings at ($6.32) EPS.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($1.55) EPS for the quarter, topping the consensus estimate of ($1.80) by $0.25. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. The company had revenue of $8.73 million during the quarter, compared to the consensus estimate of $9.86 million.

AGIO has been the topic of a number of other research reports. Scotiabank lowered their price objective on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a “sector outperform” rating on the stock in a research report on Friday, May 2nd. Wall Street Zen cut Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, May 19th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $56.50.

Agios Pharmaceuticals Stock Up 0.3%

Shares of NASDAQ AGIO opened at $34.50 on Thursday. The firm’s 50-day moving average price is $29.56 and its 200-day moving average price is $33.93. Agios Pharmaceuticals has a 52-week low of $23.42 and a 52-week high of $62.58. The company has a market cap of $2.00 billion, a PE ratio of 3.04 and a beta of 0.73.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Venturi Wealth Management LLC purchased a new stake in Agios Pharmaceuticals in the 4th quarter worth approximately $33,000. GF Fund Management CO. LTD. bought a new position in shares of Agios Pharmaceuticals in the fourth quarter worth approximately $39,000. NewEdge Advisors LLC purchased a new stake in shares of Agios Pharmaceuticals in the first quarter worth $40,000. CWM LLC raised its position in shares of Agios Pharmaceuticals by 150.2% during the 1st quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 996 shares during the period. Finally, Sterling Capital Management LLC raised its position in shares of Agios Pharmaceuticals by 818.0% during the 4th quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 1,587 shares during the period.

Insider Activity at Agios Pharmaceuticals

In related news, Director Jacqualyn A. Fouse sold 7,497 shares of Agios Pharmaceuticals stock in a transaction on Thursday, April 10th. The stock was sold at an average price of $25.90, for a total transaction of $194,172.30. Following the transaction, the director now directly owns 149,220 shares in the company, valued at approximately $3,864,798. The trade was a 4.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 4.93% of the stock is currently owned by company insiders.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.